- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05634369
A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Pediatric Bone and Soft Tissue (TINKS)
The purpose of this study is to determine if the addition of infusions of a type of immune cell called a "natural killer", or NK cell to the sarcoma chemotherapy regimen GEM/DOX (gemcitabine and docetaxel) can improve outcomes in people with childhood sarcomas that have relapsed or not responded to prior therapies.
The goals of this study are:
- To determine the safety and efficacy of the addition of adoptive transfer of universal donor, TGFβ imprinted (TGFβi), expanded NK cells to the pediatric sarcoma salvage chemotherapeutic regimen gemcitabine/docetaxel (GEM/DOX) for treatment of relapsed and refractory pediatric sarcomas To determine the 6-month progression free survival achieved with this treatment in patients within cohorts of relapsed or refractory osteosarcoma, Ewing sarcoma, rhabdomyosarcoma and non-rhabdomyosarcoma soft tissue sarcoma.
- To identify toxicities related to treatment with GEM/DOX + TGFβi expanded NK cells
Participants will receive study drugs that include chemotherapy and NK cells in cycles; each cycle is 21 days long and you can receive up to 8 cycles.
- Gemcitabine (GEM): via IV on Days 1 and 8
- Docetaxel (DOX): via IV on Day 8
- Prophylactic dexamethasone: Day 7-9 to prevent fluid retention and hypersensitivity reaction
- Peg-filgrastim (PEG-GCSF) or biosimilar: Day 9 to help your white blood cell recover and allow more chemotherapy to be given
- TGFβi NK cells: via IV on Day 12
Study Overview
Status
Intervention / Treatment
Detailed Description
This is a multi-center study with rolling safety and toxicity analysis, to determine the safety and efficacy of the addition of adoptive transfer of universal donor, TGFβ imprinted (TGFβi), expanded NK cells to the pediatric sarcoma salvage chemotherapeutic regimen gemcitabine/docetaxel (GEM/DOX) for treatment of relapsed and refractory pediatric sarcomas, identify toxicities related to treatment with GEM/DOX + TGFβi expanded NK cells, and assess in vivo persistence of expanded, universal donor, TGFβi NK cells after adoptive transfer and correlate with clinical outcomes.
The planned therapy will involve 8 cycles of 21 days each consisting of gemcitabine, docetaxel, supportive dexamethasone and peg-filgrastim, and universal donor, TGFβi ex vivo expanded NK cells (Cycles 1-6).
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Jessica Crimella, BSN, RN, CCRP
- Phone Number: 813-745-6250
- Email: jessica.crimella@moffitt.org
Study Locations
-
-
Florida
-
Saint Petersburg, Florida, United States, 33701
- Not yet recruiting
- Johns Hopkins All Children's Hospital
-
Principal Investigator:
- Jonathan Metts, MD
-
Contact:
- Jonathan Metts, MD
- Phone Number: 727-767-4176
- Email: jmetts1@jhmi.edu
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Recruiting
- Washington University/St Louis Childrens
-
Principal Investigator:
- Amy Armstrong, MD
-
Contact:
- Amy Armstrong, MD
- Phone Number: 314-454-6018
- Email: armstrongae@wustl.edu
-
-
New York
-
Bronx, New York, United States, 10467
- Recruiting
- Montefiore Medical Center
-
Principal Investigator:
- Alice Lee, MD
-
Contact:
- Alice Lee, MD
- Phone Number: 718-741-2342
- Email: alee5@montefiore.org
-
Buffalo, New York, United States, 14263
- Recruiting
- Roswell Park Comprehensive Cancer Center
-
Principal Investigator:
- Ajay Gupta, MD
-
Contact:
- Ajay Gupta, MD
- Phone Number: 716-845-2333
- Email: Ajay.Gupta@RoswellPark.org
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Recruiting
- Duke Children's Hospital/Duke Health
-
Principal Investigator:
- Jessica Sun, MD
-
Contact:
- Jessica Sun, MD
- Phone Number: 919-668-1102
- Email: jessica.sun@duke.edu
-
-
Ohio
-
Columbus, Ohio, United States, 43205
- Recruiting
- Nationwide Children's Hospital
-
Principal Investigator:
- Bhuvana Setty, MD
-
Contact:
- Clelie Peck
- Phone Number: 614-722-5634
- Email: clelie.peck@nationwidechildrens.org
-
-
Texas
-
Dallas, Texas, United States, 75390
- Not yet recruiting
- UT Southwestern
-
Principal Investigator:
- Matthew Campbell, MD
-
Contact:
- Matthew Campbell, MD
- Phone Number: 214-456-2382
- Email: Matthew.Campbell@UTSouthwestern.edu
-
Houston, Texas, United States, 77030
- Recruiting
- University of Texas MD Anderson Cancer Center
-
Sub-Investigator:
- Jonathan Gill, MD
-
Contact:
- Jonathan Gill, MD
- Phone Number: 713-745-3145
- Email: jbgill@mdanderson.org
-
Contact:
- Dristhi Ragoonanan, MD
- Phone Number: 713-792-6620
- Email: DRagoonanan@mdanderson.org
-
Principal Investigator:
- Dristhi Ragoonanan, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients must be between the ages > 12 years and ≤ 40 years of age and have had a relapsed or refractory osteosarcoma, Ewing sarcoma, rhabdomyosarcoma or non-rhabdomyosarcoma soft tissue sarcoma.
- Patients must have measurable disease using RECIST 1.1 criteria
- Patients must have had at least one and no more than four total lines of systemic treatment for relapse sarcoma. Local control with surgical resection or radiation therapy of the primary tumor and any metastatic sites as clinically indicated as standard of care per the treating physician must be considered prior to enrollment.
Prior Therapy: Therapy may not have been received more recently than the timeframes defined below:
- Myelosuppressive chemotherapy: Patients must not have received myelosuppressive therapy within 14 days of protocol therapy
- Radiation: At least 2 weeks must have elapsed from the start of protocol therapy since local palliative XRT (small port); 4 weeks must have elapsed for all other radiation therapy
- Hematopoietic Cell Transplant (HCT): Patients must have at least 6 weeks elapsed after autologous and allogeneic hematopoietic cell transplant
- Biologic (anti-neoplastic agent): At least 7 days or 5 half-lives of the drug, whichever is longer, must have elapsed from the start of protocol therapy since the completion of therapy with a biologic agent.
- Monoclonal antibodies: At least 3 weeks must have elapsed from the start of protocol therapy since prior therapy that included a monoclonal antibody.
- Prior use of Gemcitabine and/or Docetaxel: Patients who have received these agents for prior treatment may be included if previous treatments were given ≥ 6 months prior to enrollment on this study, and there were no allergic reactions, pulmonary edema or fibrosis, Grade 3 or higher neuropathy or other non-hematologic Grade 4 adverse events related to gemcitabine and/or docetaxel therapies.
4) Performance status: Karnofsky ≥ 60 for patients ≥16 years of age. Lansky score of ≥ 60 for patients < 16 years of age (see Appendix A) 5) Organ Function Requirements: Patients must have normal organ and marrow function within 7 days of starting protocol therapy as defined below:
- Absolute Neutrophil Count ≥1000/mcL
- Platelet count ≥100,000/mcL independent of transfusion
- Total bilirubin < 1.5x upper limit of normal for age
- AST(SGOT)/ALT(SGPT) ≤ 2.5 x institutional upper limit of normal
- Serum creatinine < 1.5 x upper limit of normal based on age/gender (Table 3) OR creatinine clearance ≥70 mL/min/1.73 m2 for patients with creatinine levels above institutional normal
Shortening fraction ≥ 27% by ECHO OR ejection fraction of ≥ 50% by ECHO or gated radionuclide study
- Echocardiogram done within 12 months of study entry will be acceptable. If patient has required anthracycline chemotherapy since last ECHO and enrollment on this study, echocardiogram should be repeated.
No evidence for dyspnea at rest, no chronic oxygen requirement, and room air pulse oximetry >94% if there is a clinical indication for pulse oximetry 6) Neuropathy: Patients must have ≤ Grade 2 neuropathy at enrollment 7) Patients with seizure disorders may be enrolled if seizures are well controlled on anti-convulsant, with the exception of diazepam given its potential deleterious effects on NK cell activity.
8) Contraception: The effects of expanded NK cells on the developing human fetus are unknown. For this reason and because the chemotherapeutic preparative agents as well as other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of preparatory regimen administration.
9) All patients and/or their parents or legal guardians must have the ability to understand and the willingness to sign a written informed consent/assent document.
Exclusion Criteria:
- Patients who are receiving any other investigational agents.
- Patients must not be receiving any additional medicines being given for the specific purpose of treating cancer
- Patients with a history of allergic reactions attributed to docetaxel, gemcitabine, or peg-filgrastim or biosimilar
- Patients who have received any prior cellular therapies, such as CAR-T cells or other expanded or manufactured cellular products.
- Patients with bone marrow only disease are not eligible for this study.
- Patients who, in the judgment of the treating physician, has tumors near critical structures for which transient swelling would cause substantial symptoms, such as tumor within the bowel mucosa
- Patients with CNS metastatic disease will not be eligible for this study.
Concomitant Medications:
- Due to their effect on NK cell function, systemic corticosteroids outside of the supportive dexamethasone given from day 7 through 9 should be used ONLY for life-threatening conditions (i.e., life-threatening allergic reactions and anaphylaxis such as bronchospasm, stridor) unresponsive to other measures. The use of dexamethasone as an anti-emetic is not permitted. Corticosteroid therapy can be used as a premedication for transfusion in patients known to have a history of transfusion reactions or for treatment of an unexpected transfusion reaction (hydrocortisone 2 mg/kg or less or an equivalent dose of an alternative corticosteroids). The use of steroids during protocol therapy other than the study- required prophylactic dexamethasone doses requires clear justification and documentation of use for a life-threatening condition.
The following are also prohibited while on study treatment
- Strong CYP3A4 inducers. Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated list such as http://medicine.iupui.edu/clinpharm/ddis/; medical reference texts such as the Physicians' Desk Reference may also provide this information.
- Diazepam
- Chemotherapeutic agents other than the study drugs
Uncontrolled intercurrent illness including, but not limited to:
- ongoing or active infection
- psychiatric illness/social situations that would limit compliance with study requirements
- Pregnancy or Breast-Feeding: Pregnant or breast-feeding woman will not be entered on this study due to risks of fetal and teratogenic adverse events as seen in animal/human studies with Gemcitabine and Docetaxel
- HIV Infection: HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with the study medications. In addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy. Appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
- Patients who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study are not eligible.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment
Part 1: Enrollment of 5 patients in each cohort (osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, and non-rhabdomyosarcoma). Part 2: Enrollment of 2 cohorts in 2 stages for a total of 40 patients. |
8 cycles consisting of gemcitabine, docetaxel, supportive dexamethasone and pegfilagrastim, and universal donor, TGFBi ex vivo expanded NK cells
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part 1
Time Frame: 3-5 years
|
Evaluation of DLT in patients enrolled during Part 1 enrollment
|
3-5 years
|
Part 2
Time Frame: 3-5 years
|
Determination of 6-month progression free survival (PFS) in study patients measured from initiation of treatment (Day 1 of the first cycle of therapy) Patients will be considered evaluable for tumor response if they:
|
3-5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment response of target lesions determined using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Time Frame: Every two cycles (21 days per cycle) for 3-5 years
|
Assessments will be performed after every other cycle of treatment to determine antitumor effect of therapy.
|
Every two cycles (21 days per cycle) for 3-5 years
|
Frequency and characterization of DLT in study patients
Time Frame: 3-5 years
|
cycle = 21 days
|
3-5 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Exploratory Endpoint
Time Frame: Days 1, 8, and 12 of each cycle (21 days per cycle), starting with cycle 2
|
Assessment of TGFβi NK cell persistence, phenotype, and retained cytolytic activity in patient peripheral blood via samples drawn on days 1, 8, and 12 of each cycle beginning with cycle 2 analyzed by flow cytometry.
|
Days 1, 8, and 12 of each cycle (21 days per cycle), starting with cycle 2
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Bhuvana Setty, MD, Nationwide Children's Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Neoplasms
- Sarcoma
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Docetaxel
- Dexamethasone
- Gemcitabine
Other Study ID Numbers
- MCC21704
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pediatric Sarcoma, Refractory
-
Samsung Medical CenterMinistry of Health, Republic of KoreaRecruitingRelapsed Pediatric AML | Refractory Pediatric AML | Relapsed Pediatric Solid Tumor | Refractory Pediatric Solid TumorKorea, Republic of
-
Fred Hutchinson Cancer CenterIncyte CorporationActive, not recruitingRefractory Soft Tissue Sarcoma | Metastatic Leiomyosarcoma | Metastatic Synovial Sarcoma | Metastatic Undifferentiated Pleomorphic Sarcoma | Advanced Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma | Advanced Synovial Sarcoma | Metastatic Chondrosarcoma | Advanced Leiomyosarcoma | Metastatic Myxoid... and other conditionsUnited States
-
Samsung Medical CenterMinistry of Health, Republic of KoreaNot yet recruitingRelapsed Pediatric Solid Tumor | Refractory Pediatric Solid TumorKorea, Republic of
-
Gustave Roussy, Cancer Campus, Grand ParisInnovative Therapies For Children with Cancer ConsortiumUnknownRelapsed or Refractory Pediatric TumorFrance, Ireland, Israel, Italy, Spain
-
Dana-Farber Cancer InstituteCompletedRefractory Ewing Sarcoma | Refractory Osteosarcoma | Relapsed Ewing Sarcoma | Relapsed OsteosarcomaUnited States
-
Sun Yat-sen UniversityNanjing Geneseeq Technology Inc.RecruitingPediatric Soft Tissue SarcomaChina
-
University of California, San FranciscoDana-Farber Cancer Institute; UCSF Benioff Children's Hospital Oakland; Alex's...CompletedSarcoma | Refractory SarcomaUnited States
-
Peking University People's HospitalCompletedSoft Tissue Sarcoma | Bone Sarcoma | Refractory TumorChina
-
University of OxfordAstellas Pharma Inc; European Organisation for Research and Treatment of Cancer... and other collaboratorsCompletedRefractory Ewing Sarcoma | Relapsed Ewing SarcomaUnited Kingdom, Germany, Netherlands, Italy, France
-
OncoTherapy Science, Inc.TerminatedRelapsed or Refractory Synovial SarcomaJapan
Clinical Trials on GEM/DOX + TGFBi expanded NK cells
-
Peking University People's HospitalRecruitingTransplantation Infection | CMV ViremiaChina
-
Belarusian Research Center for Pediatric Oncology...RecruitingAcute Myeloid LeukemiaBelarus
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingRecurrent Gliosarcoma | Recurrent Supratentorial Glioblastoma | Supratentorial GliosarcomaUnited States
-
University Hospital, Basel, SwitzerlandCompleted
-
Sumithira VasuKiadis PharmaRecruitingRecurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Blasts 10 Percent or More of Bone Marrow Nucleated Cells | Allogeneic Stem Cell Transplant RecipientUnited States
-
University of Wisconsin, MadisonNational Cancer Institute (NCI); Solving Kids' Cancer; Wade's Army; Midwest Athletes... and other collaboratorsWithdrawnOsteosarcoma | Neuroblastoma | Recurrent Neuroblastoma | Relapsed NeuroblastomaUnited States
-
National University Hospital, SingaporeUnknownEwing Sarcoma | RhabdomyosarcomaSingapore
-
Margaret Gatti-MaysRecruitingAnatomic Stage IV Breast Cancer AJCC v8 | HER2-Negative Breast CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingRefractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Recurrent Cutaneous Melanoma | Recurrent Malignant Female Reproductive System Neoplasm | Refractory Malignant Female Reproductive System Neoplasm | Recurrent Lip and Oral Cavity Carcinoma | Recurrent Malignant Endocrine... and other conditionsUnited States
-
Joaquín Martínez López, MD, PhDHospital Infantil Universitario Niño Jesús, Madrid, SpainCompleted